Thanks BK, Leo is very excited about the potential GI applications of Brilacidin. I can see this both in his response to your questions and in his response to a recent query of my own about an old PR. LEO RESPONDED as below:
Last week I was traveling and I am now catching up on emails. At this time we are focused on Kevetrin and our defensin mimetics for creating additional applications. For example Brilacidin as an anti inflammatory would be a significantly greater market than as an antibiotic. Think GI diseases! Thats why we are anxiously waiting to see what happens in the OM trial.
Market Data 
Markets 
AI
